Catch up quickly with The OncoBrief, your weekly digest of the top three oncology stories that matter most. Delivered clearly and concisely, we cover clinical breakthroughs, FDA approvals, and emerging trends keeping oncologists informed and ahead.
Radiation Oncology Consolidation, Neuropathy Prevention, and New Immunotherapy for HCC
Love what you hear? Download the Curie app from the App Store today (https://curie.md/app.html?utm_source=podcastplatforms&utm_medium=social&utm_campaign=normal&utm_term=doctors&utm_content=podcast).
Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.
In this episode of Curie, Matt covers three key updates in oncology. A new analysis shows that radiation oncology practices are consolidating rapidly, raising concerns about access to care, patient choice, and job stability for oncologists. In breast cancer, a randomized trial finds that hand cooling and compression can significantly reduce chemotherapy-induced neuropathy, offering a simple, cost-effective strategy to protect patients’ nerves. And finally, the EMA has recommended expanding nivolumab plus ipilimumab for advanced hepatocellular carcinoma, positioning it as an alternative to the current standard of care. Tune in for the latest insights shaping cancer treatment.
21 Mar 2025
MRD in AML, Early-Phase Cancer Trials Reality Check, and the Hospital-at-Home Debate
Love what you hear? Download the Curie app from the App Store today (https://curie.md/app.html?utm_source=podcastplatforms&utm_medium=social&utm_campaign=normal&utm_term=doctors&utm_content=podcast).
Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.
In this episode of Curie, Matt covers three important topics shaping cancer care. A new study confirms that achieving MRD negativity early in AML is critical for long-term survival, reinforcing MRD’s growing role in treatment decisions. We then explore the hard truth about early-phase cancer trials, revealing that only 16.2% of phase 2 treatments ever gain FDA approval—what does this mean for patients enrolling in these studies? Finally, we examine the rapid expansion of Hospital-at-Home care, a model that could change oncology treatment, but also raises concerns about patient safety and healthcare equity. Tune in for the latest updates and insights.
21 Mar 2025
Datopotamab Deruxtecan Approved, Immunotherapy Timing, and Rising Early-Onset Colorectal Cancer
In this episode of Curie, Matt covers three major developments in oncology. The FDA has approved datopotamab deruxtecan (Datroway) for HR positive, HER2 negative breast cancer, marking a new era for antibody-drug conjugates in this disease. A meta-analysis suggests that the timing of immunotherapy infusions may impact survival outcomes, raising questions about how circadian rhythms influence treatment response. Finally, a global analysis confirms that early-onset colorectal cancer is on the rise worldwide, challenging current screening guidelines and prompting discussions on prevention strategies. Tune in for the latest insights shaping cancer care.
Podcast Authority Score: 30 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
60
Social presence
0
YouTube
0
Engagement
0
Contact Curie: The Oncology Brief
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Curie: The Oncology Brief?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
